News
Martin Kerschensteiner receives ERC Advanced Grant
Martin Kerschensteiner is elected as the new BMC Speaker
June 2026: The European Research Council will provide substantial funding for the research proposal “TACO – Targeting myeloid cell states, actions and interactions in neuroinflammation”. With this project Martin Kerschensteiner and his team aim to leverage advanced CRISPR screening approaches to better understand and target the role of ...
February 2026: Ten years after its founding, the Biomedical Center of the LMU Munich has seen its first change in leadership following the retirement of Peter Becker. Martin Kerschensteiner who previously served as deputy speaker will take over as BMC speaker and Antje Grosche and Michael Kiebler are the new...
Publications
Pathogenic autoantibodies to synaptophysin in cerebellar ataxia
In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation
June 2026 – Cerebellar ataxias encompass a wide spectrum of genetic and sporadic origins, a proportion of which are driven by immune-mediated pathomechanisms. Here the labs of Simone Mader and Edgar Meinl together with multicenter collaborations identified synaptophysin (SYP) as an ...
February 2026 – Here the Kerschensteiner lab developed a new CRISPR-based in vivo screening platform that reveals how cytokines orchestrate macrophage behavior in multiple sclerosis. By editing progenitor cells before transplantation, they mapped how key immune signals—like IFN-γ,TNF ...